A Unique
Discovery Engine
Threading Them Together
At Molecular Axiom, we believe in harnessing the knowledge of disease and the precision of nucleic acid medicine to solve complex health issues. A broad and deep understanding of biology will allow the best selection of therapeutic targets, or a combination therapy. Extensive expertise in various nucleic medicine mechanisms and delivery strategies allow us to create the best nucleic acid drug formats and the most effective delivery routes to treat the diseases.
Disease Biology
Targets & Combinations
Drug Delivery
Achievable &
Efficient Vehicles
Drug Biology
Suitable Formats &
Modifications
Current Pipeline
- Multiple USPTO patents filed
- Multiple projects going into animal studies, to enter IND enabling by year end
| Tissue | Target | Modality | Indication | Discovery | Lead Identification |
IND Enabling |
Phase 1 |
| Lung |  SOS 1 |
RNase H | Lung Cancer | 26 | |||
| KRAS G12C |
RNase H | Lung Cancer | 37 | ||||
| KRAS G12D |
RNase H | Lung Cancer | 26 | ||||
| KRAS G12V |
RNase H | Lung Cancer | 37 | ||||
| KRAS G12A |
RNase H | Lung Cancer | 26 | ||||
| Undisclosed | RNase H | Lung Cancer | 26 | ||||
| Undisclosed | mRNA | Lung Cancer | 26 | ||||
| CNS | NLRP3/1 | RNase H | Neurodegenerative | 37 | |||
| Undisclosed | RNase H | Neurodegenerative | 13 | ||||
| Skin | Undisclosed | RNase H | Immunology | 37 | |||
| Blood | Undisclosed | Undisclosed | Immunology | 13 | |||
| Undisclosed | Undisclosed | Cancer | 13 | ||||
 Patents Filed  Development Candidate |
Alzheimer’s, Parkinson’s, Huntington, ALS, brain and spinal cord injuries | ||||||
Lipid Nanoparticle (LNP):
Our proprietary Boundless-LNP® delivery platform is currently under development. Compared to the current generation of LNPs, our Boundless-LNP® is designed to deliver not only enhanced safety, pharmacokinetics, and endosomal release, but most importantly the ability to target various tissues and cell types, which will greatly broaden the therapeutic reach of nucleic acid medicines as a whole.